New Drug Futures (Cardiovascular)
Products that could change the pharma market to 2010 and beyond
| Price: £695.00 Approx $1,349.69 (USD) €1,038.06 (EUR) |
|
|---|---|
| Overview: | |
| This chapter of New Drug Futures evaluates, compares and contrasts the prospects for the compounds that will revolutionise the pharmaceutical industry over the next 5 years and beyond in the cardiovascular sector. The report includes unique sales forecasts by major product | |
|
This paper is available from one of our partner sites.
Click here for details and to download it. |
|
By Dr CL Barton / Publication Date: 19th May 2006
Contents:
CURRENT MARKET SIZE 1
ADDRESSABLE PATIENT POPULATION . 4
CURRENT TREATMENTS 5
CARDIOVASCULAR SALES DRIVERS 6
CARDIOVASCULAR SALES BREAKERS .7
FUTURE TREATMENTS 8
MARKET DYNAMICS - WINNERS & LOSERS 16
KEY DRUGS LAUNCHES BY 2010 17
KEY EVALUATION CRITERIA .18
KEY CARDIOVASCULAR DRUG LAUNCHES BY 2010 . 19
AGI 1067 (AtheroGenics/AstraZeneca) 19
Novelty/rationale for mechanism of action .19
Proof of concept/clinical data ..19
Management/clinical expertise 20
Competition within the marketplace/gaining share of voice 20
Risks associated with developing a drug within a therapeutic class 20
Filings and approval 20
Sales forecasts and assumptions 21
Competitor Ratio Analysis 21
AZD7009 (IV) (AstraZeneca)21
Novelty/rationale for mechanism of action 21
Proof of concept/clinical data ..21
Management/clinical expertise .22
Competition within the marketplace/gaining share of voice .22
Risks associated with developing a drug within a therapeutic class 22
Filings and approval ..22
Sales forecasts and assumptions .22
Competitor Ratio Analysis ..23
BAY 59-7939 (Bayer/Johnson & Johnson) .23
Novelty/rationale for mechanism of action 23
Proof of concept/clinical data .23
Management/clinical expertise 24
Competition within the marketplace/gaining share of voice 24
Risks associated with developing a drug within a therapeutic class 24
Filings and approval 25
Sales forecasts and assumption25
Competitor Ratio Analysis 25
CERA (Roche/Chugai) 26
Novelty/rationale for mechanism of action .26
Proof of concept/clinical data .26
Management/clinical expertise .26
Competition within the marketplace/gaining share of voice .27
Risks associated with developing a drug within a therapeutic class .27
Filings and approval .27
Sales forecasts and assumptions .27
Competitor Ratio Analysis 28
Cerovive (AstraZeneca) . 28
Novelty/rationale for mechanism of action 28
Proof of concept/clinical data 28
Management/clinical expertise 29
Competition within the marketplace/gaining share of voice 29
Risks associated with developing a drug within a therapeutic class .29
Filings and approval 30
Sales forecasts and assumptions 30
Competitor Ratio Analysis 30
Dronedarone (sanofi-aventis) .31
Novelty/rationale for mechanism of action .31
Proof of concept/clinical data .31
Management/clinical expertise .31
Competition within the marketplace/gaining share of voice .31
Risks associated with developing a drug within a therapeutic class 31
Filings and approval .32
Sales forecasts and assumptions 32
Competitor Ratio Analysis 32
Exjade (Novartis) ..33
Novelty/rationale for mechanism of action .33
Proof of concept/clinical data ..33
Management/clinical expertise 33
Competition within the marketplace/gaining share of voice 33
Risks associated with developing a drug within a therapeutic class .33
Filings and approval .34
Sales forecasts and assumptions .34
Competitor Ratio Analysis .35
Procoralan (Servier) .35
Novelty/rationale for mechanism of action .35
Proof of concept/clinical data 35
Management/clinical expertise 36
Competition within the marketplace/gaining share of voice .36
Risks associated with developing a drug within a therapeutic class 36
Filings and approval 36
Sales forecasts and assumptions ..36
Competitor Ratio Analysis 37
Prasugrel (Eli Lilly/Sankyo) ..37
Novelty/rationale for mechanism of action ...37
Proof of concept/clinical data .37
Management/clinical expertise ..38
Competition within the marketplace/gaining share of voice ..38
Risks associated with developing a drug within a therapeutic class .38
Filings and approval .38
Sales forecasts and assumptions ..38
Competitor Ratio Analysis .39
Ranexa (CV Therapeutics) .39
Novelty/rationale for mechanism of action ..39
Proof of concept/clinical data ..39
Management/clinical expertise .40
Competition within the marketplace/gaining share of voice 40
Risks associated with developing a drug within a therapeutic class .40
Filings and approval .40
Sales forecasts and assumptions .41
Competitor Ratio Analysis .41
Regadenoson (Astella/CV Therapeutics) .41
Novelty/rationale for mechanism of action .41
Proof of concept/clinical data .41
Management/clinical expertise 42
Competition within the marketplace/gaining share of voice ...42
Risks associated with developing a drug within a therapeutic class .42
Filings and approval .42
Sales forecasts and assumptions ..42
Competitor Ratio Analysis .43
Rasilez (Novartis) . 43
Novelty/rationale for mechanism of action 43
Proof of concept/clinical data .43
Management/clinical expertise ..44
Competition within the marketplace/gaining share of voice 44
Risks associated with developing a drug within a therapeutic class 44
Filings and approval .44
Sales forecasts and assumptions .44
Competitor Ratio Analysis .45
Revatio (Pfizer) .45
Novelty/rationale for mechanism of action .5
Proof of concept/clinical data ..45
Management/clinical expertise ..45
Competition within the marketplace/gaining share of voice .46
Risks associated with developing a drug within a therapeutic class 46
Filings and approval .46
Sales forecasts and assumptions .46
Competitor Ratio Analysis .47
Thelin (Encysive Pharmaceuticals) 47
Novelty/rationale for mechanism of action 47
Proof of concept/clinical data 47
Management/clinical expertise .48
Competition within the marketplace/gaining share of voice .48
Risks associated with developing a drug within a therapeutic class .48
Filings and approval 48
Sales forecasts and assumptions .48
Competitor Ratio Analysis .49
Torcetrapib/Lipitor (Pfizer) . 49
Novelty/rationale for mechanism of action ..49
Proof of concept/clinical data .50
Management/clinical expertise .50
Competition within the marketplace/gaining share of voice 51
Risks associated with developing a drug within a therapeutic class 51
Filings and approval 52
Sales forecasts and assumptions 52
Competitor Ratio Analysis .53
COMPETITOR RATIO ANALYSIS SUMMARY .54
COMPETITOR RATIO ANALYSIS – DRUGS 55
COMPETITOR RATIO ANALYSIS - COMPANIES ..57
CONTENTS